Storia in 9 fonti

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo5 h fa

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

originale

Timeline cronologica

sabato 6 giugno 2026·morningstar.com
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
sabato 6 giugno 2026·statnews.com
Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

Confronto fonti

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

Timeline cronologica

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Detailed data show Pfizer’s monthly obesity drug continues to show potential

AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

Here’s how GLP-1 drugs could save your life, as well as make you slim

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone

The promises and pitfalls of GLP-1 drugs

New data may cast doubt on competitiveness of Boehringer’s obesity drug

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone

Here’s how GLP-1 drugs could save your life, as well as make you slim

Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push

AstraZeneca se suma al mercado contra la obesidad, nueva pastilla da resultados alentadores en ensayo clínico

AstraZeneca rentre dans la course aux comprimés anti-obésité avec des résultats "très compétitifs"